Foster City, CA, Shanghai and Hangzhou, China, May 20, 2021 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai.
Dr. Guoliang Yu, the company's Co-Founder, Chairman and CEO said, "In 2018, we established a Chinese company in Hangzhou, and our Chinese team has grown from a few people to dozens of people. The Shanghai branch is located in the Silicon Valley of bioinnovative drugs in China, Zhangjiang Medicine Valley, which has gathered top talent from research and development, clinical and commercialization. Many of our clinical trials in China are soon to be carried out. The establishment of the Shanghai branch will be more conducive to the construction of our diverse talent team and will also promote connection and communication with domestic and foreign partners."
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. It has operating entities in Foster City, California, USA and Hangzhou, China. The company's product pipeline has many projects at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.
Contact information of Apollomics:
Wilson W. Cheung
Chief Financial Officer
U.S. Media Contact:
China Media Contact:
Porda Havas International Finance Communications Group
Telephone: (852) 3150 6763
Assistant Vice President
Telephone: (852) 3150 6773
Topic: Press release summary
Source: Apollomics, Inc.
Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network
Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.